tradingkey.logo

Genfit SA

GNFT
4.850USD
0.000
收盤 12/26, 16:00美東報價延遲15分鐘
242.51M總市值
--本益比TTM

Genfit SA

4.850
0.000

關於 Genfit SA 公司

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Genfit SA簡介

公司代碼GNFT
公司名稱Genfit SA
上市日期Dec 19, 2006
CEOPrigent (Pascal)
員工數量180
證券類型Depository Receipt
年結日Dec 19
公司地址Parc Eurasante 885 avenue Eugene Avinee
城市LOOS
上市交易所NASDAQ OMX - NASDAQ BASIC
國家France
郵編59120
電話33320164000
網址https://www.genfit.fr/
公司代碼GNFT
上市日期Dec 19, 2006
CEOPrigent (Pascal)

Genfit SA公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mr. John Brozek
Mr. John Brozek
Executive Vice President - Data and Information Technology
Executive Vice President - Data and Information Technology
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
Dr. Dean W. Hum, Ph.D.
Dr. Dean W. Hum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
其他
99.87%
持股股東
持股股東
佔比
AllianceBernstein L.P.
0.04%
Morgan Stanley & Co. International Plc
0.04%
Summit Financial, LLC
0.04%
UBS Financial Services, Inc.
0.01%
其他
99.87%
股東類型
持股股東
佔比
Investment Advisor/Hedge Fund
0.05%
Investment Advisor
0.05%
Research Firm
0.04%
其他
99.86%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
20
80.73K
0.16%
-686.95K
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
2023Q2
30
1.77M
3.54%
-496.41K
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
AllianceBernstein L.P.
22.36K
0.04%
+13.38K
+148.94%
Jun 30, 2024
Morgan Stanley & Co. International Plc
27.42K
0.05%
+1.90K
+7.45%
Jun 30, 2025
UBS Financial Services, Inc.
4.08K
0.01%
+963.00
+30.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.21K
0.01%
--
--
Aug 31, 2025
Osaic Holdings, Inc.
225.00
0%
+225.00
--
Jun 30, 2025
Principal Securities Inc
24.00
0%
+24.00
--
Jun 30, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
1.00
0%
-16.00
-94.12%
Jun 30, 2025
Millennium Management LLC
--
0%
-131.48K
-100.00%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Genfit SA的前五大股東是誰?

Genfit SA的前五大股東如下:
AllianceBernstein L.P.
持有股份:22.36K
佔總股份比例:0.04%。
Morgan Stanley & Co. International Plc
持有股份:27.42K
佔總股份比例:0.05%。
UBS Financial Services, Inc.
持有股份:4.08K
佔總股份比例:0.01%。
Geode Capital Management, L.L.C.
持有股份:3.21K
佔總股份比例:0.01%。
Osaic Holdings, Inc.
持有股份:225.00
佔總股份比例:0.00%。

Genfit SA的前三大股東類型是什麼?

Genfit SA 的前三大股東類型分別是:
AllianceBernstein L.P.
Morgan Stanley & Co. International Plc
Summit Financial, LLC

有多少機構持有Genfit SA(GNFT)的股份?

截至2025Q3,共有20家機構持有Genfit SA的股份,合計持有的股份價值約為80.73K,占公司總股份的0.16% 。與2025Q2相比,機構持股有所增加,增幅為-0.31%。

哪個業務部門對Genfit SA的收入貢獻最大?

在--,--業務部門對Genfit SA的收入貢獻最大,創收--,占總收入的--% 。
KeyAI